Evolution Analysis – Google, Sanofi, Novartis and the Race to Improve Diabetes Health Outcomes

On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools for the treatment of

Share
Evolution Announce Human Capital Partnership with Genomics Startup QuantiHealth

Evolution Global Talent Attraction recently signed a contract to provide human capital to newly formed company QuantiHealth in China. QuantiHealth was founded by Zhao Bowen, who was named as one

Share
Evolution Biopharma IPO Analysis featured on Forbes

Evolution’s 2015 Biopharmaceutical IPO Analysis was featured in a recent article on Forbes. Science & Business correspondent Arlene Weintraub’s article, titled “Will Wall Street Volatility Dampen The Sizzling Biotech IPO

Share
Evolution Infographic – An Analysis of 2015 Therapeutic IPOs

In the first half of 2015 fifty therapeutics companies finalised their IPOs, raising over $5.17 billion across multiple global exchanges. Evolution Global Talent Attraction analysed the therapeutic targets and IPO

Share
Evolution Infographic – An Analysis of Biopharmaceutical Production in EMEA

Evolution Global Talent Attraction’s latest market research report looks at the capacity and content of biopharmaceutical production in Europe, the Middle East and Africa. Rather than publish a lengthy report,

Share
Record-setting IPO for cancer immunotherapy company NantKwest

NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer,

Share
Charles River Labs to Acquire Rapid Bacterial Detection System Provider Celsis International

Preclinical CRO Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject

Share
Arysta LifeScience announce exclusive commercial partnership at Plant Impact Investors Day

Evolution Global Talent Attraction were recently invited to crop enhancement company Plant Impact’s Investors Day at Rothamsted, where Plant Impact announced the commercial launch of BANZAI, a novel product that

Share
Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies

Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic

Share
Research Chemicals Leader Alfa Aesar to be acquired by Thermo Fisher Scientific

Thermo Fisher Scientific have signed a definitive agreement to acquire Alfa Aesar, a leading global manufacturer of research chemicals, for £256 million (approximately $405 million USD) in cash. Alfa Aesar’s

Share
Genentech and Regeneron win Thomson Reuters Allicense Awards for Top BioPharma Deals of the Year

The Intellectual Property and Science business of Thomson Reuters recently honoured Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for Deals of the Year.

Share
Merck Millipore Acquire Exclusive Rights to Singulex Single Molecule Counting Technology

Merck Millipore and Singulex, the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, have announced that they have entered into a definitive

Share
Advanced Cell Diagnostics raises $22 million USD in latest round of financing

Advanced Cell Diagnostics (ACD) have raised a further $22 million in Series C equity financing, with proceeds to be used to accelerate their entry into the research and clinical diagnostics

Share
Kite Pharma & bluebird bio Announce Strategic Collaboration to Treat HPV-Associated Cancers

With the Cancer Immunotherapy market forecast to increase to $9 billion by 2022, it’s no surprise that the burgeoning sector has attracted the attention of biotech and pharma investors across

Share
Merck Acquisition of Sigma-Aldrich receives conditional clearance from European Commission

Sigma-Aldrich’s acquisition by Merck has been conditionally cleared by the European Commission, and has received full clearance from the Chinese Ministry of Commerce. Merck and Sigma have already cleared from

Share